Zoetis Inc. Business Combination, Acquisition Related Costs
Zoetis Inc. (ZTS) reported Business Combination, Acquisition Related Costs of $2.00 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2023-11-02
- Zoetis Inc. business combination, acquisition related costs for the quarter ending 2023-09-30 was $2.00M.
- Zoetis Inc. business combination, acquisition related costs for the quarter ending 2022-09-30 was $0.00.
- Zoetis Inc. business combination, acquisition related costs for the quarter ending 2019-03-31 was $5.00M.
- Zoetis Inc. business combination, acquisition related costs for the quarter ending 2018-12-31 was $1.00M.
- Zoetis Inc. business combination, acquisition related costs for fiscal 2020 was $18.00M, a 58.14% decline from fiscal 2019.
- Zoetis Inc. business combination, acquisition related costs for fiscal 2019 was $43.00M, a 29.51% decline from fiscal 2018.
- Zoetis Inc. business combination, acquisition related costs for fiscal 2018 was $61.00M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 3 month as first filed | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 9 month as first filed | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|---|---|
| 2023-09-30 | $2.00M 10-Q · filed 2023-11-02 | $4.00M 10-Q · filed 2023-11-02 | ||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||||
| 2020-12-31 | $18.00M 10-K · filed 2021-02-16 | |||||
| 2019-12-31 | $43.00M 10-K · filed 2021-02-16 | |||||
| 2019-03-31 | $5.00M 10-Q · filed 2019-05-02 | $6.00M derived: sum of 2 quarters · filed 2021-02-16 | $63.00M derived: sum of 3 quarters · filed 2021-02-16 | |||
| 2018-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $58.00M derived: sum of 2 quarters · filed 2021-02-16 | $61.00M 10-K · filed 2021-02-16 | |||
| 2018-09-30 | $57.00M 10-Q · filed 2019-11-07 | $39.00M 10-Q · filed 2018-11-01 | $60.00M 10-Q · filed 2019-11-07 | $40.00M 10-Q · filed 2018-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |